Search
Displaying 221–230 of 556 for “Retinitis pigmentosa”
-
ARVO 2024 Highlight: InGel’s Cell Therapy Shows Promise for Preserving Vision
Research NewsThe emerging treatment is designed to work for people with RP and other conditions regardless of the gene mutation causing disease
-
Research News
No serious adverse events were reported. One patient had encouraging improvement in retinal sensitivity.
-
ARVO 2024 Highlight: New Gene Linked to RP in People with African Ancestry
Research NewsThe discovery will help geneticists diagnose more RP patients with African descent.
-
Phase 3 Clinical Trial of NAC Launched for RP Patients
Research NewsThe drug is thought to work independent of the mutated gene causing RP.
-
ViGeneron Launches Clinical Trial of Gene Therapy for RP Caused by CNGA1 Mutations
Research NewsThe gene therapy is administered using a less-invasive intravitreal injection.
-
Ocugen to Launch Phase 3 Clinical Trial of Modifier Gene Therapy for RP
Research NewsThe emerging treatment is designed to work independent of the patient’s mutated gene.
-
Nanoscope Plans to Apply for FDA Approval for its Optogenetic Therapy
Research NewsThe company reported positive two-year results for its Phase 2 clinical trial of MCO-010.
-
VISIONS 2024, the national conference of the Foundation Fighting Blindness, is a one-of-a-kind event in which individuals who are visually impaired, and their families, have the opportunity to hear about exciting advancements in blindness research.
-
VISIONS 2024, the global conference of the Foundation Fighting Blindness, provides an excellent opportunity to connect with others from the blind and low vision community and learn about the latest research advancements, products and services for members of our community.
-
jCyte Announces Plans to Launch Phase 3 Clinical Trial of Cell Therapy for RP
Research NewsKnown as retinal progenitors, the company’s jCells® are designed to preserve photoreceptors in people with retinitis pigmentosa (RP) and other retinal diseases.
.png)
